Skip to main content

Table 1 Characteristics of the population (median with 25–75 percentiles)

From: Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype

 

Normal weight

n = 11

ARO

n = 10

MHO

n = 9

P a

P b

P c

Gender (m/f)

4/7

9/1

5/4

   

Age (years)

47 (42–54)

52 (43–59)

49 (42–63)

Weight (kg)

65.8 (63.1–79.1)

102.7 (96.0–113.8)

104.4 (93.3–110.6)

<0.001

<0.001

BMI (kg/m2)

23 (21–24)

32 (30–34)

33 (30–37)

<0.001

<0.001

TAG (mmol/L)

0.6 (0.4–0.9)

2.3 (1.7–2.7)

1.0 (0.8–1.3)

<0.001

<0.001

<0.001

Total cholesterol (mmol/L)

4.7 (4.2–5.0)

5.8 (5.4–6.1)

5.1 (4.3–5.2)

<0.001

0.002

HDL (mmol/L)

1.6 (1.4–2.2)

1.1 (0.9–1.1)

1.4 (1.2–1.5)

<0.001

0.032

0.001

LDL (mmol/L)

2.3 (2.1–2.6)

3.8 (3.4–3.9)

2.9 (2.6–3.3)

<0.001

0.009

0.002

Glucose (mmol/L)

5.1 (4.3–5.3)

5.6 (4.1–6.3)

5.4 (4.8–5.7)

0.044

Insulin (pmol/L)

40 (19–59)

75 (60–107)

65 (52–102)

0.001

0.012

0.033

HOMA dir

1.4 (0.6–2.0)

3.0 (2.3–4.3)

2.2 (1.7–3.7)

<0.001

0.015

0.009

HbA1c (%)

5.1 (4.9–5.4)

5.3 (5.0–5.9)

5.6 (5.3–5.7)

0.039

C-peptide (pmol/L)

482 (279–584)

942 (821–1171)

889 (754–1155)

<0.001

<0.001

hsCRP (mg/L)

0.5 (0.3–1.1)

1.6 (0.8–3.5)

2.2 (0.8–2.7)

0.020

0.033

  1. aNormal weight versus at-risk obese (ARO)
  2. bNormal weight versus metabolically healthy but obese (MHO)
  3. cARO versus MHO
  4. dHomoeostasis model assessment for insulin resistance: (fasting plasma insulin (mU/L) × fasting plasma glucose (mmol/L))/22.5 (1 mU/L = 6.945 pmol/L)